Collegium Pharmaceutical, Inc. (COLL)
USD 26.01
(5.43%)
USD 26.01
(5.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 435.33 Million USD | -37.73% |
| 2022 | 699.09 Million USD | 866.62% |
| 2021 | 72.32 Million USD | -21.78% |
| 2020 | 92.46 Million USD | 162.3% |
| 2019 | -148.42 Million USD | -9.84% |
| 2018 | -135.13 Million USD | -15.28% |
| 2017 | -117.21 Million USD | 21.37% |
| 2016 | -149.07 Million USD | -67.72% |
| 2015 | -88.88 Million USD | -881.54% |
| 2014 | 11.37 Million USD | 272.89% |
| 2013 | -6.57 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 386.56 Million USD | -3.69% |
| 2024 Q1 | 401.38 Million USD | -7.8% |
| 2023 Q4 | 435.33 Million USD | -5.33% |
| 2023 Q1 | 536.75 Million USD | -23.22% |
| 2023 Q2 | 478.6 Million USD | -10.83% |
| 2023 Q3 | 459.85 Million USD | -3.92% |
| 2023 FY | 435.33 Million USD | -37.73% |
| 2022 Q2 | 632.19 Million USD | -5.78% |
| 2022 Q1 | 670.97 Million USD | 452.28% |
| 2022 FY | 699.09 Million USD | 866.62% |
| 2022 Q4 | 699.09 Million USD | 16.91% |
| 2022 Q3 | 597.96 Million USD | -5.41% |
| 2021 Q2 | 79.74 Million USD | -28.5% |
| 2021 Q1 | 111.52 Million USD | 20.61% |
| 2021 FY | 72.32 Million USD | -21.78% |
| 2021 Q4 | 121.49 Million USD | 56.92% |
| 2021 Q3 | 77.42 Million USD | -2.91% |
| 2020 Q1 | 180.71 Million USD | 221.75% |
| 2020 Q2 | 141.07 Million USD | -21.93% |
| 2020 Q3 | 111.28 Million USD | -21.12% |
| 2020 Q4 | 92.46 Million USD | -16.91% |
| 2020 FY | 92.46 Million USD | 162.3% |
| 2019 Q2 | -126.67 Million USD | -12.31% |
| 2019 FY | -148.42 Million USD | -9.84% |
| 2019 Q4 | -148.42 Million USD | -12.46% |
| 2019 Q3 | -131.97 Million USD | -4.18% |
| 2019 Q1 | -112.79 Million USD | 16.53% |
| 2018 Q3 | -128.29 Million USD | -4.94% |
| 2018 Q4 | -135.13 Million USD | -5.33% |
| 2018 Q2 | -122.24 Million USD | -4.71% |
| 2018 FY | -135.13 Million USD | -15.28% |
| 2018 Q1 | -116.74 Million USD | 0.4% |
| 2017 Q1 | -126.07 Million USD | 15.43% |
| 2017 Q3 | -105.46 Million USD | 2.7% |
| 2017 Q4 | -117.21 Million USD | -11.14% |
| 2017 Q2 | -108.39 Million USD | 14.02% |
| 2017 FY | -117.21 Million USD | 21.37% |
| 2016 Q4 | -149.07 Million USD | -72.92% |
| 2016 Q3 | -86.21 Million USD | 18.1% |
| 2016 Q2 | -105.26 Million USD | 18.13% |
| 2016 Q1 | -128.58 Million USD | -44.66% |
| 2016 FY | -149.07 Million USD | -67.72% |
| 2015 Q2 | -104.68 Million USD | -182.22% |
| 2015 Q4 | -88.88 Million USD | 9.28% |
| 2015 FY | -88.88 Million USD | -881.54% |
| 2015 Q3 | -97.98 Million USD | 6.4% |
| 2015 Q1 | -37.09 Million USD | -426.15% |
| 2014 FY | 11.37 Million USD | 272.89% |
| 2014 Q4 | 11.37 Million USD | 0.0% |
| 2014 Q1 | 7.55 Million USD | 0.0% |
| 2013 FY | -6.57 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -23537.418% |
| Alpha Teknova, Inc. | 1.97 Million USD | -21953.495% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -362.106% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -480.835% |
| Cosmos Health Inc. | 8.59 Million USD | -4967.493% |
| Journey Medical Corporation | -9.7 Million USD | 4583.84% |
| Embecta Corp. | 1.31 Billion USD | 66.819% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 5.093% |
| Dynavax Technologies Corporation | 106.63 Million USD | -308.249% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 432.752% |
| Pacira BioSciences, Inc. | 432.74 Million USD | -0.599% |
| PainReform Ltd. | -7.95 Million USD | 5575.925% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2884.432% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2884.432% |
| SCYNEXIS, Inc. | -19.35 Million USD | 2349.798% |
| Safety Shot Inc | -2.28 Million USD | 19157.116% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 4716.632% |
| Procaps Group, S.A. | 242.93 Million USD | -79.201% |
| Theratechnologies Inc. | 24.87 Million USD | -1650.376% |
| Harrow Health, Inc. | 116.41 Million USD | -273.945% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 17375.238% |
| Biofrontera Inc. | 4.05 Million USD | -10633.136% |
| DURECT Corporation | -7.65 Million USD | 5787.693% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1398.464% |
| Cronos Group Inc. | -663.32 Million USD | 165.629% |
| OptiNose, Inc. | 58.06 Million USD | -649.739% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 30.166% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 3087.483% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 8494.396% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -2799.727% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 6945.287% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -407292.92% |
| Radius Health, Inc. | 359.28 Million USD | -21.169% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -220648.546% |
| ProPhase Labs, Inc. | 19.23 Million USD | -2163.72% |
| Phibro Animal Health Corporation | 454.84 Million USD | 4.289% |
| Procaps Group S.A. | 242.93 Million USD | -79.201% |
| Alvotech | 1.06 Billion USD | 59.097% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -11736.215% |
| Viatris Inc. | 17.13 Billion USD | 97.459% |
| Rockwell Medical, Inc. | 4.45 Million USD | -9669.659% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 9026.307% |
| SIGA Technologies, Inc. | -148.68 Million USD | 392.797% |
| Tilray Brands, Inc. | 158.97 Million USD | -173.836% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -257.131% |
| Shineco, Inc. | 29.29 Million USD | -1386.28% |
| PetIQ, Inc. | 351.93 Million USD | -23.699% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 15104.198% |
| Incannex Healthcare Limited | -5.48 Million USD | 8036.846% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -145.536% |
| Alimera Sciences, Inc. | 55.3 Million USD | -687.098% |
| Silver Spike Investment Corp. | -32.61 Million USD | 1434.91% |
| Assertio Holdings, Inc. | -32.52 Million USD | 1438.301% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 29342.263% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 8702.825% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 9143.124% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5400.264% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -10223.358% |
| Hempacco Co., Inc. | 13.61 Million USD | -3097.549% |
| Talphera, Inc. | -5.72 Million USD | 7709.439% |
| Alvotech | 1.06 Billion USD | 59.097% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -5992.876% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 550.146% |
| Currenc Group, Inc. | -16.57 Million USD | 2726.759% |
| Kamada Ltd. | -46.43 Million USD | 1037.587% |
| Indivior PLC | -33.95 Million USD | 1382.21% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -166968.088% |
| Flora Growth Corp. | -713 Thousand USD | 61156.942% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5400.264% |
| Evolus, Inc. | 63.7 Million USD | -583.33% |
| HUTCHMED (China) Limited | -197.45 Million USD | 320.47% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 9.137% |
| Akanda Corp. | 3.9 Million USD | -11048.409% |